Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants.

OBJECTIVES: To investigate whether disturbance of the cellular homoeostasis and integrity of cardiomyocytes in dilated cardiomyopathy (DCM) is accompanied by alterations in cell-matrix relations as indicated by changes in the deposition of fibronectin (FN) isoforms. DESIGN: Tissue from a case series of patients with DCM was investigated by immunohistochemistry with antibodies against FN (all variants, clone IST4), ED-A+ FN (clone IST9), ED-B+ FN (clone BC1), and oncofetal glycosylated FN (clone 5C10). The sites of de novo synthesis of FN were demonstrated by means of non-radioactive RNA in situ hybridisation (ISH) with biotinylated FN cDNA fragments as the probe. SETTING: University hospital. PATIENTS: Samples from 10 patients with clinical criteria and histological diagnosis of DCM and from 3 individuals with normal hearts. INTERVENTIONS: Samples were obtained by right ventricular endomyocardial biopsy. MAIN OUTCOME MEASURE: Distribution of oncofetal FN variants in DCM hearts. RESULTS: Immunostaining of FN (IST4, all variants) showed a coarse interstitial network in normal and diseased myocardium. ED-A+ FN was deposited as fine interstitial spots in normal myocardium and in DCM samples. Immunostaining for oncofetal glycosylated FN and ED-B+ FN was not seen in normal adult myocardium, whereas myocardium from DCM patients showed focal and delicate staining in the interstitium. RNA ISH showed that these deposits resulted from local FN synthesis. CONCLUSION: The results accord with de novo expression of oncofetal FN variants in hearts from patients with DCM. The oncofetal FN variants may serve as disease markers in myocardium affected by DCM.

[1]  P. Oliviéro,et al.  Differential splicing of fibronectin pre-messenger ribonucleic acid during cardiac ontogeny and development of hypertrophy in the rat. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[2]  S. Carsons,et al.  Expression of a developmentally regulated epitope on fibronectins from the synovial fluid of patients with rheumatic disease. , 1994, The Journal of rheumatology.

[3]  H. Clausen,et al.  Oncofetal fibronectins in oral carcinomas: , 1994, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[4]  G. Hutchins,et al.  The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. , 1994, Journal of the American College of Cardiology.

[5]  K. Olden.  Adhesion molecules and inhibitors of glycosylation in cancer. , 1993, Seminars in cancer biology.

[6]  R. Chiquet‐Ehrismann.  Tenascin and other adhesion-modulating proteins in cancer. , 1993, Seminars in cancer biology.

[7]  K. Titani,et al.  Coordinate oncodevelopmental modulation of alternative splicing of fibronectin pre-messenger RNA at ED-A, ED-B, and CS1 regions in human liver tumors. , 1993, Cancer research.

[8]  F M Watt,et al.  Regulation of development and differentiation by the extracellular matrix. , 1993, Development.

[9]  L. Zardi,et al.  The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. , 1992, The Journal of biological chemistry.

[10]  S. Hakomori,et al.  Cancer‐associated changes in glycosylation of fibronectin , 1992 .

[11]  F. Villarreal,et al.  Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen. , 1992, The American journal of physiology.

[12]  J. Schaper,et al.  The extracellular matrix in human cardiac tissue. Part II: Vimentin, laminin, and fibronectin. , 1992, Cardioscience.

[13]  J. Thiery,et al.  Accumulation of fetal fibronectin mRNAs during the development of rat cardiac hypertrophy induced by pressure overload. , 1991, The Journal of clinical investigation.

[14]  J. Schwarzbauer.  Alternative splicing of fibronectin: Three variants, three functions , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  P. Armstrong,et al.  Fibrillar collagen and remodeling of dilated canine left ventricle. , 1990, Circulation.

[16]  H. Kosmehl,et al.  Experimentally induced murine rhabdomyosarcomas--correlation between cellular contacts, matrix formation and cellular differentiation. , 1990, Differentiation; research in biological diversity.

[17]  R. Gay,et al.  Collagen profile in the transplanted heart. , 1990, Human pathology.

[18]  K. Titani,et al.  Fibronectin Pre-messenger Rna in Human Lung Tissues Oncodevelopmental Regulation of the Alternative Splicing of Updated Version Citing Articles E-mail Alerts Oncodevelopmental Regulation of the Alternative Splicing of Fibronectin Pre- Messenger Rna in Human Lung Tissues' , 2022 .

[19]  E. Arbustini,et al.  The morphologic spectrum of dilated cardiomyopathy and its relation to immune-response genes. , 1989, The American journal of cardiology.

[20]  Harold E. Dvorak,et al.  Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat , 1989, The Journal of cell biology.

[21]  R. Hynes,et al.  Alternative splicing of fibronectin is temporally and spatially regulated in the chicken embryo. , 1989, Development.

[22]  W. Abelmann,et al.  The challenge of cardiomyopathy. , 1989, Journal of the American College of Cardiology.

[23]  L. Zardi,et al.  A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors , 1989, The Journal of cell biology.

[24]  V. Koteliansky,et al.  Participance of fibronectin and various collagen types in the formation of fibrous extracellular matrix in cardiosclerosis. , 1988, Journal of molecular and cellular cardiology.

[25]  K. Titani,et al.  The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. , 1988, The Journal of biological chemistry.

[26]  B. McManus,et al.  Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. , 1987, The American journal of cardiology.

[27]  F. Baralle,et al.  Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. , 1987, The EMBO journal.

[28]  J. Taylor‐Papadimitriou,et al.  Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells , 1987, The Journal of cell biology.

[29]  S. Hakomori,et al.  The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Kornblihtt,et al.  Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. , 1985, The EMBO journal.

[31]  Z. Fuks,et al.  Differential structural requirements for the induction of cell attachment, proliferation and differentiation by the extracellular matrix. , 1985, Experimental cell research.

[32]  A. Kornblihtt,et al.  Isolation and characterization of cDNA clones for human and bovine fibronectins. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Borg.  Development of the connective tissue network in the neonatal hamster heart. , 1982, The American journal of anatomy.

[34]  M. Silver,et al.  Cardiac fibronectin: developmental distribution and quantitative comparison of possible sites of synthesis. , 1981, Journal of molecular and cellular cardiology.

[35]  T K Borg,et al.  The collagen network of the heart. , 1979, Laboratory investigation; a journal of technical methods and pathology.

[36]  L. Zardi,et al.  Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues. , 1947, Journal of cell science.

[37]  M. Sobrinho-Simões,et al.  Immunohistochemical expression of oncofetal fibronectin in benign and malignant lesions of the stomach. , 1993, European journal of cancer.

[38]  T. Borg,et al.  Extracellular matrix expression, organization and interaction with heart myocytes during development and disease , 1993 .

[39]  T Takahashi,et al.  Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. , 1993, Cancer research.

[40]  J. Schaper,et al.  The extracellular matrix in the failing human heart. , 1992, Basic research in cardiology.

[41]  J. Riou,et al.  Tenascin: a potential modulator of cell‐extracellular matrix interactions during vertebrate embryogenesis , 1992, Biology of the cell.

[42]  T. Parker,et al.  Growth factors, proto-oncogenes, and plasticity of the cardiac phenotype. , 1991, Annual review of physiology.

[43]  H. Kosmehl,et al.  Differentiation dependent matrix formation (fibronectin and laminin) in an experimental murine rhabdomyosarcoma model. , 1991, Acta histochemica.

[44]  J. Schwarzbauer.  The Fibronectin Gene , 1990 .

[45]  T. Borg,et al.  Interaction of the extracellular matrix with cardiac myocytes during development and disease , 1990 .

[46]  K. von der Mark,et al.  Antagonistic effects of laminin and fibronectin on the expression of the myogenic phenotype. , 1989, Differentiation; research in biological diversity.

[47]  T. Borg,et al.  Cellular adhesion to artificial substrates and long term culture of adult cardiac myocytes , 1988 .